stock.name

Delcath Systems Inc

DCTH

Market Cap$206.17M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Delcath Systems IncDelcath Systems Inc00%---
$22.00

Target Price by Analysts

188% upsideDelcath Systems Target Price DetailsTarget Price
$-4.30

Current Fair Value

156.3% downside

Overvalued by 156.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$206.17 Million
Enterprise Value-
Dividend Yield$0.0 (0.0%)
Earnings per Share$0.0
Beta0.0
Outstanding Shares27,785,803
Avg 30 Day Volume243,548

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio0.0
PEG-
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Delcath Systems Inc

CEO: Jennifer Simpson

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...